121 related articles for article (PubMed ID: 18687023)
1. Atomoxetine-associated hemospermia: a case report.
Raj YP
J Clin Psychiatry; 2008 Jul; 69(7):1189. PubMed ID: 18687023
[No Abstract] [Full Text] [Related]
2. [The practice and problem of therapeutic agents for AD/HD].
Tanaka H; Miyajima T
No To Hattatsu; 2010 May; 42(3):213-6. PubMed ID: 23858580
[No Abstract] [Full Text] [Related]
3. Treatment of adult ADHD and comorbid disorders.
Young JL
CNS Spectr; 2006 Oct; 11(10 Suppl 11):10-2. PubMed ID: 17712918
[No Abstract] [Full Text] [Related]
4. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
Niederhofer H
Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
[No Abstract] [Full Text] [Related]
6. Methylphenidate and atomoxetine for treatment of nocturnal enuresis in a child with attention-deficit hyperactivity disorder.
Bahali K; Ipek H; Uneri OS
Eur Child Adolesc Psychiatry; 2013 Oct; 22(10):649-50. PubMed ID: 23553575
[No Abstract] [Full Text] [Related]
7. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
Eiland LS; Bell EA; Erramouspe J
Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
[TBL] [Abstract][Full Text] [Related]
8. [Medical treatments of hyperactive child].
Le Heuzey MF
Arch Pediatr; 2004 Jan; 11(1):64-9. PubMed ID: 14700769
[TBL] [Abstract][Full Text] [Related]
9. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
Ni HC; Shang CY; Gau SS; Lin YJ; Huang HC; Yang LK
Int J Neuropsychopharmacol; 2013 Oct; 16(9):1959-73. PubMed ID: 23672818
[TBL] [Abstract][Full Text] [Related]
10. Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome.
Jaworowski S; Benarroch F; Gross-Tsur V
J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):365-70. PubMed ID: 16768644
[TBL] [Abstract][Full Text] [Related]
11. Sleep disturbances and ADHD medications.
Rostain AL
Curr Psychiatry Rep; 2007 Oct; 9(5):399-400. PubMed ID: 17915079
[No Abstract] [Full Text] [Related]
12. [Atomoxetine in ADHD: caution].
Karila L
Rev Prat; 2011 Nov; 61(9 Suppl):S7-8. PubMed ID: 22338199
[No Abstract] [Full Text] [Related]
13. Non-stimulant trials of adult ADHD.
Adler LA
CNS Spectr; 2007 Apr; 12(4 Suppl 6):11-3. PubMed ID: 17717871
[No Abstract] [Full Text] [Related]
14. Methylphenidate vs atomoxetine: personalized medicine in attention- deficit/hyperactivity disorder.
Heinrich H; Studer P; Moll GH; Kratz O
JAMA Psychiatry; 2013 May; 70(5):545. PubMed ID: 23636880
[No Abstract] [Full Text] [Related]
15. Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit/hyperactivity disorder: a (1)H magnetic resonance spectroscopy study.
Husarova V; Bittsansky M; Ondrejka I; Dobrota D
Psychiatry Res; 2014 Apr; 222(1-2):75-83. PubMed ID: 24679996
[TBL] [Abstract][Full Text] [Related]
16. How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis.
van Wyk GW; Hazell PL; Kohn MR; Granger RE; Walton RJ
J Atten Disord; 2012 May; 16(4):314-24. PubMed ID: 21289234
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
Stuhec M; Munda B; Svab V; Locatelli I
J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
[TBL] [Abstract][Full Text] [Related]
18. Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder.
Hazell P
Australas Psychiatry; 2004 Dec; 12(4):369-75. PubMed ID: 15715810
[TBL] [Abstract][Full Text] [Related]
19. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
20. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.
Bushe CJ; Savill NC
J Psychopharmacol; 2014 Mar; 28(3):204-11. PubMed ID: 23438503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
